Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China.

Trial Profile

Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 01 Nov 2011 Results published in the Chinese Medical Journal.
  • 06 Jul 2010 Registrational comment added and comment about regulatory requirement.
  • 06 Jun 2010 Patient recruitment details and results were presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum. Results of the study were not provided in the abstract.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top